RT Book, Section
A1 McDevitt, Pamela W.
A1 Frame, James N.
A1 Schwartzberg, Lee S.
A2 Boyiadzis, Michael M.
A2 Frame, James N.
A2 Kohler, David R.
A2 Fojo, Tito
SR Print(0)
ID 1128367507
T1 Indications for Growth Factors in Hematology-Oncology
T2 Hematology-Oncology Therapy, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071637893
LK hemonc.mhmedical.com/content.aspx?aid=1128367507
RD 2024/04/19
AB EpidemiologyFebrile  neutropenia  is  a  major  dose-limiting  toxicity  of  chemotherapy.  Studies  have  demonstrated  that  selective  use  of  colony-stimulating  factors  (CSFs)  in  patients  at  high-risk  for  complications  of  neutropenia  can  enhance  cost-effectiveness  by  reducing  the  risk,  severity  and  duration  of  febrile  neutropenia